Margaret Dugan
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Whitehawk Shares Real-World Mucin 16 Data; Stifel Adds Coverage. Whitehawk Therapeutics presented two real‑world studies that support its Mucin‑16 platform. In the same week, Stifel began coverage and set a $9 price target. The company’s current price sits below that target, and the stock is near a key support level at $3.99. These developments add new information for investors to consider.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Schrödinger (SDGR) Announces New Battery Research, Analyst Targets Rise. Schrödinger’s research team published a study in Nature that provides new insights into lithium‑ion battery chemistry, showcasing the company’s computational chemistry capabilities. Analyst houses TD Cowen and BMO Capital each lifted their price targets, citing the potential impact of the battery work and broader AI applications. At the same time, other analysts expressed mixed views on the company’s AI growth, resulting in a modest upward adjustment to its fair‑value estimate.
Transaction History
| ONC | ▲ Buy | Grant | 18,980 | $0 | 6/11/2026 | View on chart |
| ONC | ▼ Sell | Open Market | 212 | $66K | 5/22/2026 | View on chart |
| WHWK | ▲ Buy | Grant | 19,132 | $75K | 5/14/2026 | View on chart |
| SDGR | ▼ Sell | Open Market | 1,395 | $29K | 10/16/2025 | View on chart |
| ONC | ▲ Buy | Grant | 10,985 | $0 | 5/21/2025 | View on chart |
| SDGR | ▲ Buy | Grant | 12,500 | $0 | 3/3/2025 | View on chart |
| SDGR | ▼ Sell | Open Market | 1,531 | $27K | 10/15/2024 | View on chart |
| ONC | ▲ Buy | Grant | 16,341 | $0 | 6/5/2024 | View on chart |
| SDGR | ▲ Buy | Grant | 15,000 | $0 | 8/9/2023 | View on chart |
| ONC | ▲ Buy | Grant | 12,922 | $0 | 6/15/2023 | View on chart |
| ONC | ▲ Buy | Grant | 16,692 | $0 | 6/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List
BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List. BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.